The New York Stock Exchange ended the session with Pfizer jumping 2.08% to $37.51 on Wednesday while the New York Stock Exchange jumped 0.78% to $14,433.60.
Pfizer today's close was $37.51, 14.85% below its 52-week high of $43.08.
News about Pfizer today
Pfizer near accord to supply additional vaccine doses to U.S.. According to today's article on Bloomberg Quint, "The deal would involve the U.S. government using its authority to help prioritize Pfizer's orders with suppliers of various components needed to make the vaccine. ", "Moncef Slaoui, the chief scientific adviser to Operation Warp Speed, said in an interview with Bloomberg last week that Pfizer had asked the U.S. to exercise the Defense Production Act in order to get additional equipment and materials so it could scale up quickly and deliver more doses in the second quarter of 2021."
Pfizer nears deal to supply more vaccine. According to today's article on The Wall Street Journal, "The federal government is advancing toward a deal with Pfizer Inc. to secure 100 million more doses of the company's Covid-19 vaccine, according to people familiar with the matter, an agreement that would bolster the vaccination campaign under way in the U.S.", "Under the terms in discussion, Pfizer would provide the additional doses by July for nearly $2 billion, according to one person familiar with the discussions."
Bioinvent receives $3 million payment related to selection of antibodies under collaboration with Pfizer inc.. According to today's article on Business Insider, "LUND, Sweden, Dec. 23, 2020 /PRNewswire/ -- BioInvent International AB (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that Pfizer Inc. ("Pfizer") (NYSE: PFE) has selected antibodies directed at a previously-selected target under the companies' cancer immunotherapy research collaboration and license agreement.", "BioInvent's CEO Martin Welschof said: "Pfizer's selection of antibodies under our agreement is a great demonstration of the actionable leads generated by our drug discovery technology platform. "
Pfizer & biontech agree with U.S. government to supply 100 mln additional doses of Covid-19 vaccine. According to today's article on Business Insider, "Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced a second agreement with the U.S. government to supply an additional 100 million doses of COVID-19 Vaccine. ", "The U.S. government has the option to acquire up to an additional 400 million doses of the Pfizer-BioNTech Vaccine."
Pfizer, biontech to supply U.S. with an additional 100 million doses of Covid-19 vaccine for about $2 billion. According to today's article on MarketWatch, "Pfizer Inc. and BioNTech SE announced Wednesday a second agreement with the U.S. government to supply an additional 100 million doses of its COVID-19 vaccine for $1.95 billion. "
Pfizer to supply U.S. with 100 million more vaccine doses. According to today's article on Bloomberg Quint, "Like Pfizer's vaccine, Moderna's is a two-shot regimen. ", "In July, the U.S. had agreed to pay $1.95 billion for an initial 100 million doses from Pfizer, with an option to buy 500 million more. "
Pfizer, biontech to supply U.S. with 100 million more doses of Covid-19 vaccine. According to today's article on MarketWatch, "Pfizer Inc. and BioNTech SE announced Wednesday a second agreement with the U.S. government to supply an additional 100 million doses of its COVID-19 vaccine for $1.95 billion. "
Pfizer's Sales
Pfizer's sales growth is a negative 9.7% for the present quarter and a decline by 0.5% for the next. The company's growth estimates for the ongoing quarter and the next is a negative 9.1% and a negative 8.8%, respectively.
Pfizer's Revenue
Year-on-year quarterly revenue growth declined by 4.3%, now sitting on 48.65B for the twelve trailing months.
Pfizer's Stock Yearly Top and Bottom Value
Pfizer's stock is valued at $37.51 at 16:37 EST, way under its 52-week high of $43.08 and way above its 52-week low of $26.45.
Pfizer's Moving Average
Pfizer's worth is under its 50-day moving average of $37.77 and higher than its 200-day moving average of $35.33.Previous days news about Pfizer
Pfizer, biontech covid vaccine wins european backing. According to Bloomberg Quint on Mon Dec 21, "Pfizer Inc. and BioNTech SE's Covid-19 vaccine won the backing of the European medicines regulator, clearing the way for inoculations to start before the end of the year as the continent struggles with rising death rates and tighter lockdowns."
Pfizer, biontech covid vaccine receives european backing. According to Bloomberg Quint on Mon Dec 21, "Pfizer Inc. and BioNTech SE's Covid-19 vaccine won European approval, clearing the way for inoculations to start before the end of the year as the continent struggles with rising death rates and tighter lockdowns.", "Pfizer's Covid vaccine is the first to gain clearance in the EU, a turning point in the battle against a virus that has ravaged the continent. "
Pfizer and biontech receive CHMP positive opinion for their Covid-19 vaccine. According to Business Insider on Mon Dec 21, "This release contains forward-looking information about Pfizer's efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and modRNA candidate BNT162b2 (including qualitative assessments of available data, potential benefits, expectations for clinical trials, the pending conditional marketing authorization (CMA) application in the EU, other regulatory submissions, the anticipated timing of regulatory submissions, regulatory approval or authorization and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. ", "Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer."
Pfizer partner biontech ready to boost vaccine capacity for 2021. According to Bloomberg Quint on Mon Dec 21, "Read More: Pfizer-BioNTech Shot Likely Beats New Covid Strain, EMA Says", "Pfizer Inc. partner BioNTech SE is pursuing all its options to make more Covid-19 vaccine doses than the 1.3 billion the companies have promised to produce next year, according to the German company's chief executive officer."
Mexico close to start vaccination with delivery of Pfizer shot. According to Bloomberg Quint on Tue Dec 22, "Pfizer will send more than 1.4 million vaccines to Mexico by the end of January, Foreign Minister Marcelo Ebrard said during President Andres Manuel Lopez Obrador's daily press briefing in Mexico City on Tuesday.", "Brazil, in the meantime, still has to reach a deal with Pfizer to use its vaccine in the region's largest country."